Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.32 -0.5%	$8.99	$6.38 ▼ $17.30	$901.61M	1.45	1.27 million shs	1.27 million shs
MLYS Mineralys Therapeutics	$13.73 -0.4%	$14.84	$8.24 ▼ $18.38	$894.86M	-0.17	521,045 shs	1.07 million shs
PVLA Palvella Therapeutics	$20.51 -3.4%	$23.79	$6.20 ▼ $29.27	$226.75M	-0.1	77,701 shs	42,590 shs
RCUS Arcus Biosciences	$8.53 -1.9%	$8.73	$6.50 ▼ $18.98	$901.08M	0.83	876,576 shs	846,882 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	-0.21%	-0.53%	+8.75%	-40.26%
MLYS Mineralys Therapeutics	0.00%	-7.98%	-14.72%	-18.61%	+16.45%
PVLA Palvella Therapeutics	0.00%	-22.37%	-11.71%	-27.11%	+2,050,999,900.00%
RCUS Arcus Biosciences	0.00%	-8.92%	-3.68%	-4.59%	-46.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.981 of 5 stars	3.5	1.0	2.1	1.7	0.6
MLYS Mineralys Therapeutics	2.9303 of 5 stars	3.4	3.0	2.5	4.2	0.0
PVLA Palvella Therapeutics	4.059 of 5 stars	4.6	0.0	3.2	4.2	0.6
RCUS Arcus Biosciences	1.9036 of 5 stars	4.5	0.0	1.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	94.92% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	134.89% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	125.67% Upside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	182.69% Upside

Current Analyst Ratings Breakdown

Latest PVLA, RCUS, AVDL, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.33	N/A	N/A	$0.77 per share	12.10
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PVLA Palvella Therapeutics	$42.81M	5.30	N/A	N/A	$5.58 per share	3.68
RCUS Arcus Biosciences	$258M	3.50	N/A	N/A	$5.30 per share	1.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	155.33	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest PVLA, RCUS, AVDL, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
MLYS Mineralys Therapeutics	N/A	26.48	26.48
PVLA Palvella Therapeutics	N/A	8.84	8.84
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
MLYS Mineralys Therapeutics	84.46%
PVLA Palvella Therapeutics	40.11%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
MLYS Mineralys Therapeutics	25.56%
PVLA Palvella Therapeutics	20.50%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	92.10 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

PVLA, RCUS, AVDL, and MLYS Headlines

Recent News About These Companies

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.com

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on RCUS FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in May

June 4, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What Happened

June 4, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

June 4, 2025 | marketbeat.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.com

Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg

June 2, 2025 | thepharmaletter.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...

June 1, 2025 | gurufocus.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

June 1, 2025 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?

May 31, 2025 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

May 30, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

May 27, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLC

May 25, 2025 | marketbeat.com

Arcus Biosciences describes new c-Kit inhibitors

May 24, 2025 | bioworld.com

Woodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

May 22, 2025 | marketbeat.com

Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 9.90%

May 15, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, RCUS, AVDL, and MLYS Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.32 -0.05 (-0.53%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.32 0.00 (0.00%)

As of 06/18/2025 04:33 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mineralys Therapeutics NASDAQ:MLYS

$13.73 -0.05 (-0.36%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$13.00 -0.73 (-5.32%)

As of 06/18/2025 07:27 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Palvella Therapeutics NASDAQ:PVLA

$20.51 -0.73 (-3.44%)

As of 06/18/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Arcus Biosciences NYSE:RCUS

$8.53 -0.17 (-1.91%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$8.52 -0.02 (-0.22%)

As of 06/18/2025 07:11 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time